Key facts
- It has raised $30.0M across 1 recorded rounds; the latest was Early Stage VC ($27.3M) in Aug 2025.
- Notable investors include Founders Fund, Lux Capital, Definition, OpenAI.
- Valthos has filed 1 Form D with the SEC, most recently Apr 2026 ($27.3M sold to 5 investors).
- Status: Privately Held (backing).
Investors
4- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Valthos
Funding rounds
1 roundsAbout Valthos
Developer of a biological-intelligence platform designed to identify and counter emerging biological threats. The company offers AI systems that map and anticipate evolutionary biology changes, combined with medical-countermeasure design workflows, enabling national security and public health agencies to respond proactively to biological hazards.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Website
- valthos.com/
- Ownership
- Privately Held (backing)
Valthos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valthos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valthos in its N-PORT filings yet. We sweep new filings monthly.